Method for control of hyperlipidemia

Details Method for control of hyperlipidemia Method for control of hyperlipidemia

1988-07-27

1989-09-12

Robinson, Douglas W.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

514384, A61K 3153, A61K 3141

Patent

active

048660582

ABSTRACT:
The present invention is directed to a method of controlling hyperlipidemia in mammals which comprises administering to a mammal an amount effective to control hyperlipidemia of a compound having hypolipidemic activity and the structural formula: ##STR1## wherein R.sup.1 is hydrogen, a C.sub.1 to C.sub.18 alkyl or substituted alkyl, a C.sub.2 to C.sub.18 alkenyl or substituted alkenyl, a C.sub.2 to C.sub.18 alkynyl or substituted alkynyl, a C.sub.4 to C.sub.10 cycloalkyl or substituted cycloalkyl, a C.sub.4 to C.sub.10 cycloalkenyl or substituted cycloalkenyl, phenyl, a substituted phenyl, cyano, phenalkyl, --CO--R.sup.9 or --Y--CO--R.sup.9 ;

REFERENCES:
patent: 3267114 (1965-12-01), Wolf
patent: 3484451 (1967-04-01), Moon et al.
patent: 3555152 (1967-04-01), Moon et al.
patent: 3621099 (1969-03-01), Jacobson et al.
patent: 3634445 (1968-08-01), Zschoche et al.
patent: 4087534 (1974-05-01), Ovida et al.
patent: 4088767 (1978-05-01), Shigematsu et al.
patent: 4366320 (1980-07-01), Gilbertson
patent: 4433085 (1984-02-01), Rottmaier et al.
CA 95: 200,0151c, Korobitsyna et al. (1981).
CA 100: 87234, Rodina et al. (1984).
Chapman, John, J., Master's Thesis, "The Reaction of Carbene Precursors with Electron Deficient cis-Azo Compounds", catalogued in James E. Shepard Memorial Library (date uncertain).
Mitchell, John A., Master's Thesis, "Synthesis of 6-Carbethoxy-3-Aryl-1,3,5-Triazine-2,4 (1H, 3H)-Diones from Bicyclic Diaziridines", catalogued in James E. Shepard Memorial Library (approximately 1986).
Izydore, R. A., "1,2-Addition Reaction of Ethyl Diazoacetate and 4-Phenyl-1,2,4-Triazoline-3,5-Dione", JACS, 97 (19), 5611-12 (1975).
Presentation at the Eleventh Annual MBRS Symposium, 1983, Abstract enclosed.
Presentation at the 175th ACS National Meeting, 1978, Paper ORGN 114, Abstract enclosed.
CA 95(25): 220015k, Zh. Org. Khim., 17(9), 2021-2022.
CA 83(21): 177770r, Izydore et al., J. Am. Chem., Soc., 97(19), 5611-5612, (1975).
CA 100(12): 87234j, Khim. Geterotsiki. Soedin., (12), 1694-1695.
CA 97(19): 162927n, Pharmazie, 37(5), 355-356, 1982.
CA 84(21): 160141e, BG Appl. 73/120377, Oct. 25, 1973.
CA 82(5): 26145u, BG Appl. 21,720, Oct. 25, 1972.
CA 103(19): 156291b, Biochem. Med., 34(1), 60-69.
CA 103(17): 137521k, Biochem. Med., 34(1), 70-82.
CA 99(11): 84849p, J. Protozool., 30(1), 36-40.
CA 98(3): 13472d, Int. J. Parasitol., 12(5), 377-382.
CA 96(1): 2855p, Aust. J. Exp. Biol. Med. Sci., 59(4), 477-490.
CA 71(25): 120792x, Collect. Czech. Chem. Commun., 34(10, 3189-3190.
CA 71(19): 87946a, Biochem. Biophys. Acta, 185, 186-197.
CA 68(17): 76682y, Biochem. Biophys. Acta, 155(2), 623-625.
CA 107(19): 173715t, Jpn. J. Pharmacol., 45(1), 37-43, 1987.
CA 100(15): 114452n, Adv. Exp. Med. Biol., 165A (Purine Metab. Man-4, Pt. A), 175-178.
CA 97(25): 213834q, Proc. Soc. Exp. Biol. Med., 170(4), 476-485.
CA 90(19): 145664n, Life Sci., 23(22), 2239-2244.
CA 106(23): 192090f, Biomed. Chromatogr., 1(3), 109-118.
CA 103(19): 156291b, Biochem. Med., 34(1), 60-69.
CA 102(23): 199725t, Am. J. Physiol., 248 (4, Pt. 2), F574-F584.
CA 102(3): 20981y, Mol. Mekh, Izmen. Nasledstvennoi Inf. Mikroorg., 63-79, edited by: Maurinyla, Kh. A. Latv. Gos. Univ.: Riga, USSR.
CA 102(1): 3167v, Molekul. Mekhanizmy Izmeneniya Nasledstven. Inf. u Mikroorganizmov, Riga 62-79, From: Ref. Zh., Fiz.-Khim. Biol. Biotekhnol. 1984, Abstr. No. 10B10.
CA 101(25): 227294b, Mol. Biochem. Parasitol., 12(2), 153-171.
CA 101(21): 186788v, Biochem. Pharmacol., 33(15), 2383-2395.
CA 101(19): 163579p, Nippon Yakurigaku Zasshi, 84(3), 293-301.
CA 100(21): 172694d, Nihon Univ. J. Med., 25(6), 369-379.
CA 99(21): 173966s, Mie Igaku, 26(4), 483-492.
CA 77(1): 128n, Biochem. Pharmacol., 21(5), 607-617.
CA 69(5): 17856f, Collect. Czech. Chem. Commun., 33(6), 1778-1787.
CA 68(5): 20678j, Biochem. Biophys. Acta, 149(1), 314-316, 1967.
CA 107(7): 54712e, Biomed. Biochem. Acta, 46(5), 307-315, 1987.
CA 86(25): 183914u, Z. Naturforsch., B: Anorg. Chem., Org. Chem., 32B(4), 447-452, 1977.
CA 67(22): 103902h, Chem. Commun., (14), 693-694, 1967.
CA 105(23): 208822p, Tetrahedron, 42(2), 747-751.
CA 103(11): 87874e.
CA 94(11): 76452k, Jpn. J. Pharmacol., 30(6), 829-840.
CA 94(1): 233u, Adv. Exp. Med. Biol., 122A (Purine Metab. Man-3: Clin. Ther. Aspects), 269-276.
CA 93(15): 148764t, Rev. Rhum. Mal. Osteo-Articulaires, 47(6), 393-398, 1980.
CA 93(7): 65635a, Ann. Trop. Med. Parasitol., 74(2), 109-114, 1980.
CA 93(5): 46609d, Nucl. Acid Chem., vol. 1, 93-95, edited by: Townsend, Leroy, B.; Tipson, R. Stuart, Wiley: New York, N.Y. 1978.
CA 91(19): 151263t, Clin. Exp. Hypertens., 1(4), 487-508.
CA 91(7): 49181c, J. Pharm. Sci., 68(5), 651-652.
CA 90(1); 6364b, Nucleic Acid Chem., vol. 1, 93-95, edited by: Townsend, Leroy, B.; Tipson, R. Stuart, Wiley: New York, N.Y.
CA 91(23): 193262x, J. Org. Chem., 44(22), 3769-3778, 1979.
CA 105(23): 208822p, Tetrahedron, 42(2), 747-751.
CA 88(3): 22848b, J. Chem. Res (S), (10), 239, 1977.
CA 104(11): 88351q, Tetrahedron Lett., 26(26), 3173-3176.
CA 91(8): 66743e, Acta Crystallorg., Sect. B, B35(6), 1509-1512.
CA 90(18): 141759z, Ozone/Chlorine Dioxide Oxide, Prod. Org. Mater., Proc. Conf., Meeting Date 1976, 284-290, edited by: Rice, Rip G.; Cotruvo, Joseph A., Ozone Press Int.: Cleveland, Ohio.
CA 89(16): 135042y, Jt. Conf. Sens. Environ. Pollut., (Conf. Proc.), 4th Meeting Date 1977, 507-510/ACS: Washington, D.C.

Affiliated with

Also associated with

Rating

Method for control of hyperlipidemia does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method for control of hyperlipidemia, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for control of hyperlipidemia will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-916418